Search research articles
Contact Us
Filters
Showing results (21-30 of 237) with videos related to
Page
of 24
Sort By:
Archives of Dermatology
|
July 20, 2011
Rituximab for severe mucous membrane pemphigoid: safe enough to be drug of first choice?
Michael Hertl, Philippe Bernard, Luca Borradori
The Journal of Clinical Investigation
|
May 4, 2006
T cell control in autoimmune bullous skin disorders
Michael Hertl, Rüdiger Eming, Christian Veldman
Dermatology (Basel, Switzerland)
|
April 27, 2007
Rituximab (anti-CD20 monoclonal antibody)--ultimate or first choice in pemphigus?
Michael Hertl, Rüdiger Eming, Luca Borradori
The Journal of Investigative Dermatology
|
January 17, 2009
B-cell-directed therapy for inflammatory skin diseases
Angela Nagel, Michael Hertl, Rüdiger Eming
Therapeutische Umschau. Revue Therapeutique
|
September 1, 2010
[Autoimmune bullous skin disorders]
Michael Hertl, Andrea Niedermeier, Luca Borradori
Dermatologie (Heidelberg, Germany)
|
November 14, 2024
[Skin fragility in autoimmune blistering diseases of the skin]
Farzan Solimani, Dario Didona, Michael Hertl
Italian Journal of Dermatology and Venereology
|
July 9, 2024
Ostraceous psoriasis in a male patient with AIDS
Dario Didona, Jacqueline Kussini, Michael Hertl
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
December 17, 2009
[Scaling erythemas in an infant]
Simone Heimann, Michael Hertl, Jan Skrzypek
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
September 20, 2021
Laudatio zum 80. Geburtstag von David R. Bickers, M.D
Michael Hertl, Jean Krutmann, Hans Merk
Immunology
|
September 20, 2008
Desmoglein 3-specific T regulatory 1 cells consist of two subpopulations with differential expression of the transcription factor Foxp3
Christian Veldman, Andreas Pahl, Michael Hertl
Page
of 24
Search research articles
Search
Showing results (21-30 of 237) with videos related to
Sort By:
Page
of 24
Archives of Dermatology
|
July 20, 2011
Rituximab for severe mucous membrane pemphigoid: safe enough to be drug of first choice?
Michael Hertl, Philippe Bernard, Luca Borradori
The Journal of Clinical Investigation
|
May 4, 2006
T cell control in autoimmune bullous skin disorders
Michael Hertl, Rüdiger Eming, Christian Veldman
Dermatology (Basel, Switzerland)
|
April 27, 2007
Rituximab (anti-CD20 monoclonal antibody)--ultimate or first choice in pemphigus?
Michael Hertl, Rüdiger Eming, Luca Borradori
The Journal of Investigative Dermatology
|
January 17, 2009
B-cell-directed therapy for inflammatory skin diseases
Angela Nagel, Michael Hertl, Rüdiger Eming
Therapeutische Umschau. Revue Therapeutique
|
September 1, 2010
[Autoimmune bullous skin disorders]
Michael Hertl, Andrea Niedermeier, Luca Borradori
Dermatologie (Heidelberg, Germany)
|
November 14, 2024
[Skin fragility in autoimmune blistering diseases of the skin]
Farzan Solimani, Dario Didona, Michael Hertl
Italian Journal of Dermatology and Venereology
|
July 9, 2024
Ostraceous psoriasis in a male patient with AIDS
Dario Didona, Jacqueline Kussini, Michael Hertl
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
December 17, 2009
[Scaling erythemas in an infant]
Simone Heimann, Michael Hertl, Jan Skrzypek
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
September 20, 2021
Laudatio zum 80. Geburtstag von David R. Bickers, M.D
Michael Hertl, Jean Krutmann, Hans Merk
Immunology
|
September 20, 2008
Desmoglein 3-specific T regulatory 1 cells consist of two subpopulations with differential expression of the transcription factor Foxp3
Christian Veldman, Andreas Pahl, Michael Hertl
Page
of 24